Last reviewed · How we verify

LENOGRASTIM (GRANOGYTE 34)

Sanofi · FDA-approved active Small molecule

LENOGRASTIM (GRANOGYTE 34) is a Granulocyte colony-stimulating factor (G-CSF) Small molecule drug developed by Sanofi. It is currently FDA-approved for Chemotherapy-induced neutropenia, Bone marrow transplantation support, Severe congenital neutropenia.

Lenograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells in bone marrow.

Lenograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells in bone marrow. Used for Chemotherapy-induced neutropenia, Bone marrow transplantation support, Severe congenital neutropenia.

At a glance

Generic nameLENOGRASTIM (GRANOGYTE 34)
SponsorSanofi
Drug classGranulocyte colony-stimulating factor (G-CSF)
TargetG-CSF receptor (GCSFR)
ModalitySmall molecule
Therapeutic areaOncology, Hematology
PhaseFDA-approved

Mechanism of action

Lenograstim binds to G-CSF receptors on hematopoietic progenitor cells, promoting their maturation into functional neutrophils and releasing them into circulation. This increases neutrophil counts and enhances their antimicrobial activity, helping to prevent or treat neutropenia and associated infections in patients undergoing chemotherapy or bone marrow transplantation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about LENOGRASTIM (GRANOGYTE 34)

What is LENOGRASTIM (GRANOGYTE 34)?

LENOGRASTIM (GRANOGYTE 34) is a Granulocyte colony-stimulating factor (G-CSF) drug developed by Sanofi, indicated for Chemotherapy-induced neutropenia, Bone marrow transplantation support, Severe congenital neutropenia.

How does LENOGRASTIM (GRANOGYTE 34) work?

Lenograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells in bone marrow.

What is LENOGRASTIM (GRANOGYTE 34) used for?

LENOGRASTIM (GRANOGYTE 34) is indicated for Chemotherapy-induced neutropenia, Bone marrow transplantation support, Severe congenital neutropenia, Mobilization of peripheral blood progenitor cells for autologous transplantation.

Who makes LENOGRASTIM (GRANOGYTE 34)?

LENOGRASTIM (GRANOGYTE 34) is developed and marketed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What drug class is LENOGRASTIM (GRANOGYTE 34) in?

LENOGRASTIM (GRANOGYTE 34) belongs to the Granulocyte colony-stimulating factor (G-CSF) class. See all Granulocyte colony-stimulating factor (G-CSF) drugs at /class/granulocyte-colony-stimulating-factor-g-csf.

What development phase is LENOGRASTIM (GRANOGYTE 34) in?

LENOGRASTIM (GRANOGYTE 34) is FDA-approved (marketed).

What are the side effects of LENOGRASTIM (GRANOGYTE 34)?

Common side effects of LENOGRASTIM (GRANOGYTE 34) include Bone pain, Headache, Fatigue, Fever, Injection site reactions, Splenomegaly.

What does LENOGRASTIM (GRANOGYTE 34) target?

LENOGRASTIM (GRANOGYTE 34) targets G-CSF receptor (GCSFR) and is a Granulocyte colony-stimulating factor (G-CSF).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing